In situ gelling nasal inserts for influenza vaccine delivery

References

• Mestecky J, Moldoveanu Z, Michalek SM, Morrow CD, Compans RW, Schafer DP, . (1997). Current options for vaccine delivery by mucosal routes. J Control Release, 48:243–57.
   Web of Science ®Google Scholar
• Merkus FWHM, Verhoef JC. (1994). Nasal drug delivery: Trends and Perspectives. In: Swarbrick J, Boyian JC, eds. Encyclopedia of pharmaceutical technology, vol. 10. New York: Marcel Dekker Inc., 191–220.
   Google Scholar
• Kuper FC, Koornstra PJ, Hameleers DMH, Biewenga J, Spit BJ, Duijvestijn AM, . (1992). The role of the nasopharyngeal lymphoid tissue. Immunol Today, 13(6):219–24.
   PubMedGoogle Scholar
• Jones N. (2001). The nose and the paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev, 51:5–19.
   PubMed Web of Science ®Google Scholar
• Gallichan WS, Rosenthal KL. (1995). Specific secretory immune response in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine, 13:1589–95.
   PubMed Web of Science ®Google Scholar
• Rudin A, Riise GC, Holmgren J. (1999). Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun, 67:2884–90.
   PubMed Web of Science ®Google Scholar
• Isaka M, Yasuda Y, Mizokami M, Kozuka S, Taniguchi T, Matano K, . (2001). Mucosal immunization against hepatits B virus by intranasal coadministration of recombinant hepatitis B surface antigen and recombinant cholera toxain B subunit as adjuvant. Vaccine, 19:1460–6.
   PubMed Web of Science ®Google Scholar
• Lofthouse S. (2002). Immunological aspects of controlled antigen delivery. Adv Drug Deliv Rev, 54:863–70.
   PubMed Web of Science ®Google Scholar
• Kemp JM, Kajihara M, Nagahara S, Sano A, Brandon M, Lofthouse S. (2002). Continuous antigen delivery from controlled release implants induces significant and anamnestic immune response. Vaccine, 20:1089–98.
   PubMed Web of Science ®Google Scholar
• Glueck R. (2001). Review of intranasal influenza vaccine. Adv Drug Deliv Rev, 51:203–11.
   PubMed Web of Science ®Google Scholar
• Barchfeld GL, Hessler AL, Chen M, Pizza M, Rappuoli R, Van Nest GA. (1999). The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine, 17(7–8):695–704.
   PubMed Web of Science ®Google Scholar
• Greer CE, Petracca R, Buonamassa DT, Di Tommaso A, Gervase B, Reeve RL, . (2001). The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunization with human papillomavirus type 6b (HPV-6b) virus-like particles. Vaccine, 19(9–10):1008–12.
   Web of Science ®Google Scholar
• de Haan A, Geerligs HJ, Huchshorn JP, van Scharrenburg GJM, Palache AM, Wilschut J. (1995). Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an coadministered liposomes. Vaccine, 13:155–62.
   PubMed Web of Science ®Google Scholar
• Guy B, Pascal N, Françon A, Bonnin A, Gimenez S, Lafay-Vialon E, . (2001). Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine, 19:1794–805.
   PubMed Web of Science ®Google Scholar
• Ray R, Glaze BJ, Moldoveanu Z, Compans RW. (1985). Intranasal immunization with envelop glycoproteins of human parainfluenza virus type 3. J Infect Dis, 157:648–54.
   Google Scholar
• Plante M, Jones T, Allard F, Torossian K, Gauthier J, St-Felix N, . (2001). Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine, 20(1–2):218–25.
   PubMed Web of Science ®Google Scholar
• Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, . (2000). Carbohydrate biopolymers enhance antibody response to mucosally delivered vaccine antigens. Infect Immun, 68(10):5764–70.
   PubMed Web of Science ®Google Scholar
• Nally JE, Artiushin S, Sheoran AS, Burns PJ, Simon B, Gilley RM, . 2000. Induction of mucosal and systemic antibody specific for SeMF3 of Streptococcus equi by intranasal vaccination using a sucrose acetate isobutyrate based delivery system. Vaccine, 19:492–7.
   PubMed Web of Science ®Google Scholar
• Shahin R, Leef M, Eldridge J, Hudson M, Gilley R. (1995). Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun, 63:1195–200.
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I, Lin W, Kistner O, Davis SS, Illum L. (2001). Polymeric lamellar substrate particles for intranasal vaccination. Adv Drug Deliv Rev, 51:97–111.
   PubMed Web of Science ®Google Scholar
• van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, Junginger HE. (2003). Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine, 21(13–14):1400–8.
   PubMed Web of Science ®Google Scholar
• McInnes F, Thapa P, Stevens H, Baillie A, Watson D, Nolan A, . (2000). Nasal absorption of nicotine in sheep from a lyophilised insert formulation. AAP Pharm Sci 2000 AAPS Annu Meet, (Suppl 2):2121.
   Google Scholar
• Werner U, Damgé C, Maincent P, Bodmeier R. (2004). Properties of in situ gelling nasal insert containing estradiol/methyl β-cyclodextrin. J Drug Del Sci Tech, 14(4), 275–84.
   Web of Science ®Google Scholar
• Sinyakov MS, Kharitonenkov IG, Arefev IM, Eskov AP. (1980). Influenza virus hemagglutinin: hydrodynamic properties and molecular weight. Vopr Virusol, 1:42–5.
   PubMedGoogle Scholar
• Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. (1988). Structure of the influenza virus hemagglutinin complexed with its receptor, sialic acid. Nature, 333:426–31.
   PubMed Web of Science ®Google Scholar
• Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. (1999). Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res, 16(10):1576–81.
   PubMed Web of Science ®Google Scholar
• McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, . (2000). A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine, 19:1188–98.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, . (2002). In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation, 105(2):230–5.
   PubMed Web of Science ®Google Scholar
• MacLaughlin FC, Mumper RJ, Wang J, Tagliaferri JM, Gill I, Hinchcliffe M, . (1998). Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release, 56(1–3), 259–72.
   PubMed Web of Science ®Google Scholar
• Bally MB, Harvie P, Wong FMP, Kong S, Wasan EK, Reimer DL. (1999). Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev, 38(3):291–315.
   PubMed Web of Science ®Google Scholar
• Davis SS. (2001). Nasal vaccines. Adv Drug Deliv Rev, 51:21–42.
   PubMed Web of Science ®Google Scholar
• Nilsson S. (1995). Interactions between water-soluble cellulose derivatives and surfactants: 1. The HPMC/SDS/water system. Macromolecules, 28:7837–44.
   Web of Science ®Google Scholar
• Boulmedarat L, Grossiord JL, Fattal E, Bochot A. (2003). Influence of methyl-β-cyclodextrin and liposomes on rheological properties of Carbopol 974P NF gels. Int J Pharm, 254(1), 59–64.
   PubMed Web of Science ®Google Scholar
• Gutierrez de Rubalcava C, Rodriguez JL, Duro R, Alvarez-Lorenzo C, Concheiro A, Seijo B. (2000). Interactions between liposomes and hydroxypropyl methyl cellulose. Int J Pharm, 203(1–2):99–108.
   PubMedGoogle Scholar
• Marttin E, Schipper NGM, Verhoef JC, Merkus FWHM. (1998). Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev, 29:13–38.
   PubMed Web of Science ®Google Scholar
• Ishizaka S, Sugawara I, Hasuma T, Morisawa S, Möller G. (1980). Immune responses to xanthan gum I. The characteristics of lymphocyte activation by xanthan gum, Eur J Immunol, 13:225–31.
   Google Scholar
• Hersey SJ, Jackson RT. (1987). Effect of bile salts on nasal permeability in vitro. J Pharm Sci, 76(12):876–9.
   PubMed Web of Science ®Google Scholar
• Donovan MD, Flynn GL, Amidon GL. (1990). The molecular weight dependence of nasal absorption: The effect of absorption enhancers. Pharm Res, 7(8):808–15.
   PubMed Web of Science ®Google Scholar
• Hamman JH, Stander M, Junginger HE, Kotze AF. (2000). Enhancement of paracellular drug transport across mucosal epithelial by N-trimethylchitosan chloride. STP Pharm Sci, 10:35–8.
   Google Scholar
• Skehel JJ, Bayley PM, Brown EB, Martin SR, Waterfield MD, White JM, . (1982). Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci USA, 79(4):968–72.
   PubMed Web of Science ®Google Scholar
• Izumrudov VA, Zhiryakova MV. (1999). Stability of DNA-containing interpolyelectrolyte complexes in water-salt solutions. Macromol Chem Phys, 200:2533–40.
   Web of Science ®Google Scholar